Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.
Henrich
S
S
Christopherson
R I
RI
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002051:Burkitt Lymphoma / Q000473:pathology; D045744:Cell Line, Tumor / Q000187:drug effects / Q000378:metabolism; D004249:DNA Damage; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016158:Genes, p53; D006801:Humans; D007526:Isoelectric Point; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000473:pathology; D008970:Molecular Weight; D009154:Mutation; D009363:Neoplasm Proteins / Q000737:chemistry / Q000187:drug effects* / Q000235:genetics; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D017434:Protein Structure, Tertiary; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry / Q000187:drug effects*; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
D000964:Antimetabolites, Antineoplastic; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D016159:Tumor Suppressor Protein p53; D010447:Peptide Hydrolases; D014740:Vidarabine; C024352:fludarabine